Hôpital Saint André

The Department of Medical Oncology at Hôpital Saint André explores immune‑modulating strategies to enhance treatment response across several cancer types.

• Evaluation of PD‑L1 blockade in advanced solid tumors
• Combination antiretroviral regimens for treatment‑naïve HIV‑1 infection

With two investigators overseeing two active studies, the site contributes to cutting‑edge immunotherapy research in Europe.

Research at the Bordeaux oncology unit targets a broad spectrum of malignant diseases, aiming to test new targeted and cytotoxic therapies.

• Novel approaches for triple negative breast cancer
• Therapeutic evaluation in non‑small cell lung cancer
• Clinical investigation of pancreatic adenocarcinoma and hepatocellular carcinoma

The program reflects the site’s commitment to advancing cancer care for patients across multiple organ sites.

The facility conducts trials focused on improving outcomes for individuals living with HIV, comparing newer agents to established standards.

• Non‑inferiority assessment of doravirine‑based regimens in treatment‑naïve patients
• Monitoring virologic efficacy and safety in HIV‑1 infection

These studies, coordinated by two principal investigators, support the development of more accessible antiretroviral options in France.